• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone.

作者信息

Betsill W L, Rosen P P, Lieberman P H, Robbins G F

出版信息

JAMA. 1978 May 5;239(18):1863-7. doi: 10.1001/jama.239.18.1863.

DOI:10.1001/jama.239.18.1863
PMID:205686
Abstract

A follow-up period averaging 21.6 years was obtained for patients with low-grade papillary intraductal carcinoma initially treated only by biopsy between 1940 and 1950. Subsequent carcinoma was diagnosed in the same breast in seven of the ten patients after an average interval of 9.7 years. Six of the seven subsequent carcinomas were invasive. Two of the patients died of metastatic carcinoma and two were known to be alive with metastases when last contacted. Three patients were without carcinoma following mastectomy. When these results were combined with the few reports available in the literature, it appeared that at least 39% of patients with intraductal carcinoma treated by biopsy alone subsequently had clinically evident carcinoma, invariably in the same breat, with an average latent period of about ten years. This was undoubtedly a result of the multicentric nature of the disease in many patients.

摘要

相似文献

1
Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone.
JAMA. 1978 May 5;239(18):1863-7. doi: 10.1001/jama.239.18.1863.
2
Intraductal carcinoma of the breast: follow-up after biopsy only.乳腺导管内癌:仅活检后的随访
Cancer. 1982 Feb 15;49(4):751-8. doi: 10.1002/1097-0142(19820215)49:4<751::aid-cncr2820490426>3.0.co;2-y.
3
Carcinoma in situ of the breast.乳腺原位癌
Cancer. 1977 Sep;40(3):1189-93. doi: 10.1002/1097-0142(197709)40:3<1189::aid-cncr2820400330>3.0.co;2-x.
4
Cystic hypersecretory hyperplasia and cystic hypersecretory duct carcinoma of the breast. Pathology, therapy, and follow-up of 39 patients.乳腺囊性高分泌性增生及囊性高分泌性导管癌。39例患者的病理学、治疗及随访
Cancer. 1988 Apr 15;61(8):1611-20. doi: 10.1002/1097-0142(19880415)61:8<1611::aid-cncr2820610819>3.0.co;2-o.
5
Atypical lobular and papillary lesions of the breast: a follow-up study of 30 cases.
South Med J. 1978 Apr;71(4):361-4. doi: 10.1097/00007611-197804000-00004.
6
Intraductal carcinoma of the breast. A comparative study.乳腺导管内癌。一项对比研究。
Am J Surg. 1975 Dec;130(6):667-70. doi: 10.1016/0002-9610(75)90417-1.
7
Minimal breast cancer: advance or anachronism?
Can J Surg. 1985 May;28(3):252-5.
8
Clinical management of minimal breast cancer.微小乳腺癌的临床管理
Semin Surg Oncol. 1989;5(2):145-50. doi: 10.1002/ssu.2980050211.
9
Multicentric and bilateral appearance of lobular carcinoma in situ of the breast.
Acta Pathol Microbiol Scand A. 1974 Nov;82(6):730-4.
10
Needle-localized biopsy of occult breast lesions: an update.隐匿性乳腺病变的针定位活检:最新进展
Mil Med. 1992 Feb;157(2):61-4.

引用本文的文献

1
Influence of Cancerization of Lobules in Ductal Carcinoma In Situ of the Breast on the Pathological Outcomes in Mastectomy Specimens.乳腺导管原位癌中小叶癌变对乳房切除术标本病理结果的影响。
Cancers (Basel). 2025 May 12;17(10):1634. doi: 10.3390/cancers17101634.
2
Outcomes from low-risk ductal carcinoma in situ: a systematic review and meta-analysis.低危型导管原位癌的结局:系统评价和荟萃分析。
Breast Cancer Res Treat. 2024 Nov;208(2):237-251. doi: 10.1007/s10549-024-07473-w. Epub 2024 Aug 24.
3
Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance.
从导管原位癌到浸润性乳腺癌的进展:分子特征及临床意义。
Signal Transduct Target Ther. 2024 Apr 3;9(1):83. doi: 10.1038/s41392-024-01779-3.
4
MIND the translational gap: Preclinical models of ductal carcinoma in situ.注意转化差距:导管原位癌的临床前模型
Clin Transl Med. 2023 Aug;13(8):e1376. doi: 10.1002/ctm2.1376.
5
Using Machine Vision of Glycolytic Elements to Predict Breast Cancer Recurrences: Design and Implementation.利用糖酵解元件的机器视觉预测乳腺癌复发:设计与实现
Metabolites. 2022 Dec 27;13(1):41. doi: 10.3390/metabo13010041.
6
Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma.向浸润性乳腺癌的转变与肿瘤基质的结构和成分的进行性变化有关。
Cell. 2022 Jan 20;185(2):299-310.e18. doi: 10.1016/j.cell.2021.12.023.
7
Is Carboxypeptidase B1 a Prognostic Marker for Ductal Carcinoma In Situ?羧肽酶B1是导管原位癌的预后标志物吗?
Cancers (Basel). 2021 Apr 6;13(7):1726. doi: 10.3390/cancers13071726.
8
Collagen Organization in Relation to Ductal Carcinoma Pathology and Outcomes.胶原组织与导管癌病理和预后的关系。
Cancer Epidemiol Biomarkers Prev. 2021 Jan;30(1):80-88. doi: 10.1158/1055-9965.EPI-20-0889. Epub 2020 Oct 20.
9
A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast.乳腺导管原位癌主动监测试验的回顾性替代方法。
Int J Cancer. 2020 Mar 1;146(5):1189-1197. doi: 10.1002/ijc.32362. Epub 2019 May 8.
10
Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing.精准医学时代的导管原位癌生物标志物:当前和未来基于分子的检测。
Am J Pathol. 2019 May;189(5):956-965. doi: 10.1016/j.ajpath.2018.08.020. Epub 2018 Oct 29.